AndroPan™ · Andrographis paniculata (Kalmegh) extract
Built for the life you refuse to slow down for.
Kalmegh is one of the most studied plants of the Indian subcontinent. AndroPan™ is our USP-grade ethanolic extract, standardised for andrographolide, with the whole supply chain from farm to finished extract under our control.
Decades with one plant.
We have worked with Kalmegh across its entire supply chain for decades, sourcing from long-term farming partners who follow responsible agricultural practices. That history tells us how the plant behaves by region and season, and how to standardise without losing what surrounds the active.
- Botanical: Andrographis paniculata (Kalmegh) aerial parts
- Extract type: ethanolic, no harmful
- solvents Standardised for: andrographolide Grade: USP
- Recommended dose: 300 mg a day (150 mg twice daily)
What makes it different
High andrographolide
Standardised to a consistent, high active content.
USP grade
Tested to United States Pharmacopeia standards
Clean extraction
Ethanol only. No harmful solvents.
Studied in humans
Randomised, double-blind, placebo-controlled.
FIELD
STUDY DETAILS
RESEARCH NOTES
Study Design
Randomised, double-blind, parallel-group,
placebo-controlled study involving 36 adults aged
18–50 with upper respiratory tract infection symptoms
for 24–72 hours. The reported study protocol specifies
150 mg twice daily (300 mg per day) for 7 days.
Confirm participant criteria, treatment details,
and study duration against the original report.
Headline Results
- Greater improvement in cough symptoms
than placebo, as reported.(4.8x) - reported improvement
in cough score by day 7 (AndroPan™ vs placebo).(99.7% VS 20.8%) - reported improvement
by day 5.(71% VS 10%)
Verify the underlying chart, outcome definitions,
calculations, and statistical significance before
publication. Do not interpret these figures as
independently established clinical efficacy.
Additional Observation
The supplied study summary reports complete resolution
of common cold symptoms within 7 days in three
participants receiving AndroPan™; this outcome was
reportedly not observed in the placebo group.
Confirm participant-level results and the original
study wording.
Safety
The supplied summary describes the product as
well tolerated throughout the study.
Include adverse-event data and study limitations
where available. Avoid implying that a small,
short study establishes overall safety.
Summary
According to the supplied summary, participants
taking AndroPan™ showed greater improvements in
Leicester Cough Questionnaire (LCQ) and WURSS-21
scores than placebo at days 5 and 7.
Present findings as study-specific results.
Avoid unqualified claims such as “clinically proven,”
“fights infection,” or “protects against infection”
without adequate supporting evidence and regulatory
review.
REFERENCE
Published Study Citation
[Insert authors, study title, journal, publication year,
volume/pages, and DOI or permanent URL.]
Citation required
STUDY DESIGN
Randomised, Double-Blind
STUDY DURATION
7 Days
PARTICIPANTS
36 Adults
CLINICAL STUDY OVERVIEW
AndroPan™ Study Results
A structured overview of the study design, reported outcomes, safety observations, and supporting evidence.
01
Capsules
02
Tablets
03
Syrups
Formats and dosage
Made to formulate.
STUDIED DAILY DOSAGE
300 mg
A simple,
studied dose
300 mg a day, as studied.
Daily use
FORMULATION FORMATS
Built for different
product formats.
AndroPan™ can be incorporated across a wide range of consumer and functional product formats.
F.A.Q.
Explore answers to some of the most common questions about our products, research, formulations, and support.
A USP-grade ethanolic extract of Andrographis paniculata, standardised for andrographolide.
High andrographolide content, ethanol-only extraction, full traceability from farm to finished extract, and manufacture in a facility certified to NSF, FSSC 22000, GMP, ISO 9001:2015, USDA
Organic, Non-GMO Project, Halal and Kosher.
In a 7-day randomised, double-blind, placebo-controlled study, participants taking 150 mg twice daily showed 4.8 times greater improvement in cough symptoms (LCQ) than placebo, and the extract was well tolerated.
The complete study report is in the AndroPan™ dossier. Download it above or ask our team.
Certifications
Proud Members of
